OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
SAN DIEGO, Feb. 21, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Tuesday, February 28, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 73756754 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
